In its latest quarterly filing, Autonomix Medical disclosed cash sufficient to fund operations only through the third quarter of 2026, with research and development expenses rising due to intensified clinical trials. The company’s catheter-based platform integrates high-fidelity neural sensing with therapeutic radiofrequency ablation, targeting pancreatic cancer-related pain and expanding into cardiology indications supported by recent patents. Key risks include Nasdaq listing compliance by July 2026, substantial capital needs estimated between $30 million and $36 million, manufacturing scale-up challenges, and inherent clinical trial uncertainties. Progress on regulatory pathways, clinical milestones, and financing will be critical for advancing toward commercialization.